Cargando…

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

BACKGROUND: Dinaciclib is a potent inhibitor of cell cycle and transcriptional cyclin-dependent kinases. This Phase 1 study evaluated the safety, tolerability and pharmacokinetics of various dosing schedules of dinaciclib in advanced solid tumour patients and assessed pharmacodynamic and preliminary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mita, Monica M, Mita, Alain C, Moseley, Jennifer L, Poon, Jennifer, Small, Karen A, Jou, Ying-Ming, Kirschmeier, Paul, Zhang, Da, Zhu, Yali, Statkevich, Paul, Sankhala, Kamelesh K, Sarantopoulos, John, Cleary, James M, Chirieac, Lucian R, Rodig, Scott J, Bannerji, Rajat, Shapiro, Geoffrey I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672931/ https://www.ncbi.nlm.nih.gov/pubmed/28859059 http://dx.doi.org/10.1038/bjc.2017.288

Ejemplares similares

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
por: Nemunaitis, John J, et al.
Publicado: (2013)

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
por: Gojo, Ivana, et al.
Publicado: (2013)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2016)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer
por: Howard, David, et al.
Publicado: (2021)

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma
por: Nelson, Luke J, et al.
Publicado: (2022)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017)

Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy
por: Yuan, Qian, et al.
Publicado: (2022)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Bcl-x(L) inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
por: Rello-Varona, Santi, et al.
Publicado: (2019)

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib
por: Ke, Changhong, et al.
Publicado: (2020)

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
por: Murphy, Adrian G., et al.
Publicado: (2020)

Return to ovulation after Sayana Press is injected every 4 months for one year: Empirical and pharmacokinetic/pharmacodynamic modeling results()
por: Taylor, Douglas J., et al.
Publicado: (2022)

Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer
por: Shen, Xiao, et al.
Publicado: (2023)

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
por: Nemunaitis, John, et al.
Publicado: (2012)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
por: Varadarajan, Shankar, et al.
Publicado: (2015)

Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration
por: Tamura, Norihisa, et al.
Publicado: (2020)

The Question Every Executive Should Ask
por: Michelman, Paul
Publicado: (2017)

Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways
por: Tang, Hailong, et al.
Publicado: (2018)

Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
por: Carew, Jennifer S., et al.
Publicado: (2017)

Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide
por: Lawn, Joy E, et al.
Publicado: (2021)

Negotiating Pandemic Risk: On the Scandalization and Transcultural Transformation of the Swine Flu
por: Paul, Norbert W., et al.
Publicado: (2016)

Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses
por: Kuroda, Taisuke, et al.
Publicado: (2021)

Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1‐involved pathway
por: Zhao, Huayan, et al.
Publicado: (2019)

Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue
por: Alsayegh, Khaled, et al.
Publicado: (2017)

Bromodomain inhibitors a decade later: a promise unfulfilled?
por: Mita, Monica M., et al.
Publicado: (2020)

Every-Day Lessons from Every-Day Cases
por: Reed, Charles A. L.
Publicado: (1908)

Aurora B: Hooking up with cyclin-dependent kinases
por: Poon, Randy Y.C.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_debvmndie0q5h8fsq2dgtp1emu